Wall Street Zen Downgrades Radiopharm Theranostics (NASDAQ:RADX) to Strong Sell

Radiopharm Theranostics (NASDAQ:RADX) was downgraded by analysts at Wall Street Zen to a “strong sell” rating in a research note issued on Friday.

RADX has been the topic of a number of other research reports. B. Riley reiterated a “buy” rating and issued a $16.00 target price (up previously from $13.00) on shares of Radiopharm Theranostics in a report on Tuesday, December 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $15.33.

Radiopharm Theranostics Trading Down 2.4%

Shares of RADX opened at $4.93 on Friday. The company’s fifty day moving average is $5.02 and its two-hundred day moving average is $5.32. Radiopharm Theranostics has a fifty-two week low of $3.50 and a fifty-two week high of $16.25.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Radiopharm Theranostics stock. PNC Financial Services Group Inc. lifted its stake in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) by 100.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,000 shares of the company’s stock after buying an additional 8,000 shares during the period. PNC Financial Services Group Inc. owned approximately 0.20% of Radiopharm Theranostics worth $88,000 as of its most recent SEC filing.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.